Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers Read more about Meridian Agrees License Deal With Corixa[…]